 The FDA approved Eiger Biopharmaceuticals Inc NASDAQ: EIGRs lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processing-deficient progeroid laminopathies. The Palo Alto, California-based company focuses on targeted therapies for serious rate and ultra-rare diseases. 